Y. Cheng

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Byoung Chul Cho, Y. Cheng, Changdong Zhou et al. · Annals of Oncology · 2018 · 40 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway

Xufen Zheng, Yuxiang Luo, Yangjie Xiong et al. · Journal for ImmunoTherapy of Cancer · 2023 · 21 citations · Full text

Medicine, Immunology, Oncology +17

974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)

Samantha Novello, Dariusz M. Kowalski, Alexander Luft et al. · Annals of Oncology · 2022 · 16 citations

Medicine, Oncology, Pharmacotherapy +13

LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial

Binghe Xu, Qilong Zhang, Ping Zhang et al. · Annals of Oncology · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial

S. Senan, David R. Spigel, Byoung Chul Cho et al. · Annals of Oncology · 2024 · 13 citations · Full text

Medicine, Oncology, Radiation Oncology +13